Incidence and Mortality Associated with Cardiovascular Medication among Hypertensive COVID-19 Patients in South Korea.

In South Korea, beta-blockers exhibited potential benefits in lowering the incidence of COVID-19 among hypertensive patients. Furthermore, CCBs may lower the hospital mortality rate among hypertensive COVID-19 patients. These findings were also applied to the general adult population, regardless of hypertension.